Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Oncology Dominance | Merck's strong position in oncology, led by Keytruda, faces increasing competition and patent expiration concerns, prompting diversification efforts |
Pipeline Potential | Explore Merck's promising pipeline, including Winrevair for PAH and advancements in cardiovascular and immunology treatments |
Market Dynamics | Delve into Merck's global market challenges, including the reset of China Gardasil business and the competitive landscape in key therapeutic areas |
Financial Outlook | Analyst price targets range from $100 to $155, with EPS projections of $7.79 for FY 2024 and a 3.39% dividend yield |
Metrics to compare | MRK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMRKPeersSector | |
---|---|---|---|---|
P/E Ratio | 12.3x | −1.9x | −0.7x | |
PEG Ratio | 0.00 | 0.03 | 0.00 | |
Price/Book | 4.7x | 0.7x | 2.6x | |
Price / LTM Sales | 3.3x | 2.8x | 3.1x | |
Upside (Analyst Target) | 37.3% | 110.7% | 45.9% | |
Fair Value Upside | Unlock | 9.8% | 8.3% | Unlock |